Limits...
Preserved antigen-specific immune response in patients with multiple sclerosis responding to IFNβ-therapy.

Mehling M, Fritz S, Hafner P, Eichin D, Yonekawa T, Klimkait T, Lindberg RL, Kappos L, Hess C - PLoS ONE (2013)

Bottom Line: Related to pre-treatment disease activity, IFNβ reduced clinical and radiological MS disease-activity.Following influenza vaccination, frequencies of influenza-specific T cells and concentrations of anti-influenza A and B IgM and IgG increased comparably in MS-patients and in healthy controls.By showing in a cohort of MS-patients responding to IFNβ vaccine-specific immune responses comparable to controls, this study indicates that antigen-specific immune responses can be preserved under successful IFNβ-therapy.

View Article: PubMed Central - PubMed

Affiliation: Immunobiology Laboratory, Department of Biomedicine and Medical Outpatient Department, University Hospital Basel, Basel, Switzerland ; Department of Neurology and Clinical Neuroimmunology Laboratory/Department of Biomedicine, University Hospital Basel, Basel, Switzerland.

ABSTRACT

Background: Interferon-beta (IFNβ) regulates the expression of a complex set of pro- as well as anti-inflammatory genes. In cohorts of MS patients unstratified for therapeutic response to IFNβ, normal vaccine-specific immune responses have been observed. Data capturing antigen-specific immune responses in cohorts of subjects defined by response to IFNβ-therapy are not available.

Objective: To assess antigen-specific immune responses in a cohort of MS patients responding clinically and radiologically to IFNβ.

Methods: In 26 MS patients, clinical and MRI disease activity were assessed before and under treatment with IFNβ. Humoral and cellular immune response to influenza vaccine was prospectively characterized in these individuals, and 33 healthy controls by influenza-specific Enzyme-Linked Immunosorbent Assay (ELISA) and Enzyme Linked Immuno Spot Technique (ELISPOT).

Results: Related to pre-treatment disease activity, IFNβ reduced clinical and radiological MS disease-activity. Following influenza vaccination, frequencies of influenza-specific T cells and concentrations of anti-influenza A and B IgM and IgG increased comparably in MS-patients and in healthy controls.

Conclusions: By showing in a cohort of MS-patients responding to IFNβ vaccine-specific immune responses comparable to controls, this study indicates that antigen-specific immune responses can be preserved under successful IFNβ-therapy.

Show MeSH

Related in: MedlinePlus

Cellular immune response after influenza-vaccination in IFNβ-treated patients vs. healthy controls.The frequency of influenza-specific cells in IFNβ-treated patients with MS (IFNβ and healthy controls (HC) as detected by spot forming cells (SFC) in equal amounts of peripheral blood mononuclear cells (PBMC) is shown before (day 0) and at day 7, 14 and 28 after influenza vaccination (median + IQR). * indicates p<0.05.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3818403&req=5

pone-0078532-g003: Cellular immune response after influenza-vaccination in IFNβ-treated patients vs. healthy controls.The frequency of influenza-specific cells in IFNβ-treated patients with MS (IFNβ and healthy controls (HC) as detected by spot forming cells (SFC) in equal amounts of peripheral blood mononuclear cells (PBMC) is shown before (day 0) and at day 7, 14 and 28 after influenza vaccination (median + IQR). * indicates p<0.05.

Mentions: The frequency of T cells producing IFN-gamma in response to influenza-antigen was assessed by ELISpot. Before vaccination, frequencies of influenza-specific IFN-gamma secreting T cells were comparable in IFNβ-treated patients and in HC, as was the number of individuals with no detectable influenza-specific cellular response. By day 7 post-vaccination, frequencies significantly increased in both groups and reached similar levels (HD: p =  0.0093; MS- IFNβ: p = 0.025)(Fig. 3). Numbers of influenza-specific T cells remained similarly increased until day 14 post-vaccination in both study groups. By day 28 post-vaccination, frequencies of IFN-gamma-secreting cells contracted to pre-vaccination levels in both groups. The proportion of patients with a strong vaccine-specific cellular immune response (predefined cut-off: >250 SFC/106 PBMC) was also comparable in both groups at all post-vaccination time-points (data not shown). Of note, at all time points a tendency towards a higher frequency of vaccine-specific T cells in IFNβ-treated patients was evident when compared to controls. Again, in patients with MS no differences in the vaccine-induced cellular immune response were noted between the used IFNβ-preparations.


Preserved antigen-specific immune response in patients with multiple sclerosis responding to IFNβ-therapy.

Mehling M, Fritz S, Hafner P, Eichin D, Yonekawa T, Klimkait T, Lindberg RL, Kappos L, Hess C - PLoS ONE (2013)

Cellular immune response after influenza-vaccination in IFNβ-treated patients vs. healthy controls.The frequency of influenza-specific cells in IFNβ-treated patients with MS (IFNβ and healthy controls (HC) as detected by spot forming cells (SFC) in equal amounts of peripheral blood mononuclear cells (PBMC) is shown before (day 0) and at day 7, 14 and 28 after influenza vaccination (median + IQR). * indicates p<0.05.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3818403&req=5

pone-0078532-g003: Cellular immune response after influenza-vaccination in IFNβ-treated patients vs. healthy controls.The frequency of influenza-specific cells in IFNβ-treated patients with MS (IFNβ and healthy controls (HC) as detected by spot forming cells (SFC) in equal amounts of peripheral blood mononuclear cells (PBMC) is shown before (day 0) and at day 7, 14 and 28 after influenza vaccination (median + IQR). * indicates p<0.05.
Mentions: The frequency of T cells producing IFN-gamma in response to influenza-antigen was assessed by ELISpot. Before vaccination, frequencies of influenza-specific IFN-gamma secreting T cells were comparable in IFNβ-treated patients and in HC, as was the number of individuals with no detectable influenza-specific cellular response. By day 7 post-vaccination, frequencies significantly increased in both groups and reached similar levels (HD: p =  0.0093; MS- IFNβ: p = 0.025)(Fig. 3). Numbers of influenza-specific T cells remained similarly increased until day 14 post-vaccination in both study groups. By day 28 post-vaccination, frequencies of IFN-gamma-secreting cells contracted to pre-vaccination levels in both groups. The proportion of patients with a strong vaccine-specific cellular immune response (predefined cut-off: >250 SFC/106 PBMC) was also comparable in both groups at all post-vaccination time-points (data not shown). Of note, at all time points a tendency towards a higher frequency of vaccine-specific T cells in IFNβ-treated patients was evident when compared to controls. Again, in patients with MS no differences in the vaccine-induced cellular immune response were noted between the used IFNβ-preparations.

Bottom Line: Related to pre-treatment disease activity, IFNβ reduced clinical and radiological MS disease-activity.Following influenza vaccination, frequencies of influenza-specific T cells and concentrations of anti-influenza A and B IgM and IgG increased comparably in MS-patients and in healthy controls.By showing in a cohort of MS-patients responding to IFNβ vaccine-specific immune responses comparable to controls, this study indicates that antigen-specific immune responses can be preserved under successful IFNβ-therapy.

View Article: PubMed Central - PubMed

Affiliation: Immunobiology Laboratory, Department of Biomedicine and Medical Outpatient Department, University Hospital Basel, Basel, Switzerland ; Department of Neurology and Clinical Neuroimmunology Laboratory/Department of Biomedicine, University Hospital Basel, Basel, Switzerland.

ABSTRACT

Background: Interferon-beta (IFNβ) regulates the expression of a complex set of pro- as well as anti-inflammatory genes. In cohorts of MS patients unstratified for therapeutic response to IFNβ, normal vaccine-specific immune responses have been observed. Data capturing antigen-specific immune responses in cohorts of subjects defined by response to IFNβ-therapy are not available.

Objective: To assess antigen-specific immune responses in a cohort of MS patients responding clinically and radiologically to IFNβ.

Methods: In 26 MS patients, clinical and MRI disease activity were assessed before and under treatment with IFNβ. Humoral and cellular immune response to influenza vaccine was prospectively characterized in these individuals, and 33 healthy controls by influenza-specific Enzyme-Linked Immunosorbent Assay (ELISA) and Enzyme Linked Immuno Spot Technique (ELISPOT).

Results: Related to pre-treatment disease activity, IFNβ reduced clinical and radiological MS disease-activity. Following influenza vaccination, frequencies of influenza-specific T cells and concentrations of anti-influenza A and B IgM and IgG increased comparably in MS-patients and in healthy controls.

Conclusions: By showing in a cohort of MS-patients responding to IFNβ vaccine-specific immune responses comparable to controls, this study indicates that antigen-specific immune responses can be preserved under successful IFNβ-therapy.

Show MeSH
Related in: MedlinePlus